The Functional Cancer Genomics group directed by Prof. J.P. Theurillat at the Institute of Oncology Research in Bellinzona, Switzerland (http://www.ior.iosi.ch) is seeking a part-time bio-informatician in cancer research.
The successful candidate will work as part of an international team that is dedicated to understanding how new driver alterations culled from cancer genome characterization studies promote tumorigenesis, and how gathered insights can be exploited to develop precision medicines. The position offers excellent scientific opportunities in a highly stimulating and interdisciplinary environment involving close interactions between medical and basic scientists. Investigations range from projects related to:
- Use state-of-the-art bioinformatics tools to assist in the analysis of genome-wide biological datasets such as those generated in microarray and next-generation sequencing studies of the cancer transcriptome and epigenome in experimental and clinical samples
- MSc/PhD in bioinformatics, computational biology or related discipline
- Working experience in the analysis of copy number, methylation profiling, next-generation sequencing data, functional analysis, clinical response and survival data
- Excellent mathematical and statistical knowledge
- Fluency in R or Matlab and knowledge of programming/scripting language
The position is located at the Institute of Oncology Research, a leading institution in basic and translational cancer research in Southern Switzerland with state-of-the-art core facilities and competitive salaries.
“For inquiry regarding this job and submission of applications including two references please contact
Prof. Jean-Philippe Theurillat via email: firstname.lastname@example.org.
Starting date: Fall or winter 2017
Selected recent publications:
– Janouskova H, et al. Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors. Accepted for publication Nat Med 2017.
– Groner A, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 2016 PMID: 27238081
– Theurillat JP, et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014 PMID: 25278611
– Whittaker SR, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013 PMID: 23288408
– Barbieri CE1, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012 PMID: 22610119
– Theurillat JP, et al. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 2011 PMID: 21397856